Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer MAP Pharmaceuticals (UNKNOWN:MAPP.DL) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at MAP and see what CAPS investors are saying about the stock right now.

MAP facts

Headquarters (founded)

Mountain View, Calif. (2003)

Market Cap

$544.5 million



Trailing-12-Month Revenue

$3.6 million


CEO Timothy Nelson (since 2005)
Co-Founder/Chief Scientific Officer Dr. Thomas Armer (since 2003)

Return on Capital (average, past 3 years)



$114.2 million / $0


GlaxoSmithKline (NYSE:GSK)
Merck (NYSE:MRK)
Par Pharmaceutical Companies

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 34% of the 96 members who have rated MAP believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star BlacknGold, succinctly summed up the MAP bear case for our community:

MAP has no revenue and is losing large amounts of money each quarter (four in a row now). Before the recent financing deal it was worth less than $14 million on paper. Even now it's worth less than $60 million, which doesn't support a $540 million market cap.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara and The Motley Fool have no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.